BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Non-small Cell Lung Cancer (NSCLC)Hepatocellular Carcinoma (HCC)Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT03735628
- Locations
- πΊπΈ
Rocky Mountain Cancer Centers / Denver, CO, Denver, Colorado, United States
πΊπΈTower Hematology/Oncology Medical Group, Beverly Hills, California, United States
πΊπΈOrthopaedic Institute for Children, Los Angeles, California, United States
Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- Drug: BAY2315497 InjectionDrug: Darolutamide(BAY1841788)
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 63
- Registration Number
- NCT03724747
- Locations
- πΊπΈ
Tulane Medical Center, New Orleans, Louisiana, United States
π¬π§Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom
πΊπΈMemorial Sloan-Kettering Cancer Center, New York, New York, United States
A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
Terminated
- Conditions
- Non-valvular Atrial Fibrillation
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70000
- Registration Number
- NCT03715725
- Locations
- π³π΄
Many Locations, Multiple Locations, Norway
Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.
Completed
- Conditions
- Macular Degeneration
- Interventions
- Drug: Ivt. Aflibercept (Eylea, BAY86-5321)
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 554
- Registration Number
- NCT03714308
- Locations
- π©πͺ
Many locations, Multiple Locations, Germany
Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT03708133
- Locations
- π¦π·
FP Clinical Pharma, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina
Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.
Phase 1
Completed
- Conditions
- Cerebrovascular Circulation
- Interventions
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT03704519
- Locations
- π¬π§
Centre for Neuroimaging Sciences, King's College, London, United Kingdom
Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Bayer
- Registration Number
- NCT03699176
- Locations
- π―π΅
Ena Odori Clinic, Sapporo, Hokkaido, Japan
π―π΅Asahi clinic, Takamatsu, Kagawa, Japan
π―π΅Matsudo City General Hospital, Matsudo, Chiba, Japan
Accessibility to New Drugs Versus SOC in Sweden
Completed
- Conditions
- Anticoagulation
- Interventions
- Drug: Standard of care (Warfarin)
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 68056
- Registration Number
- NCT03684395
Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)
Not Applicable
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- Device: BAY987534
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 42
- Registration Number
- NCT03672383
- Locations
- π©πͺ
proDerm, Hamburg, Germany
Occurrence and Trend of Pregnancies Growing Outside the Womb (Ectopic Pregnancy) 2009-2018. A Study on a Defined Group of Persons
Completed
- Conditions
- Pregnancy, Ectopic
- Interventions
- Other: No intervention
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3922877
- Registration Number
- NCT03670784
- Locations
- πΊπΈ
Kaiser Permanente, San Francisco, California, United States
Β© Copyright 2025. All Rights Reserved by MedPath